A multinational, randomized phase iii trial of iseganan hcl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 3, 2004, Pages 674-681

  Trotti, Andy ^a   Garden, Adam ^b   Warde, Padraig ^c   Symonds, Paul ^d   Langer, Corey ^e   Redman, Rebecca ^f   Pajak, Thomas F ^g   Fleming, Tomas R ^h   Henke, Michael ⁱ   Bourhis, Jean ^j   Rosenthal, David I ^b   Junor, Elizabeth ^k   Cmelak, Anthony ^l   Sheehan, Finbarr ^m   Pulliam, Janis ^f   Devitt Risse, Patricia ^f   Fuchs, Henry ^f   Chambers, Mark ^b   O'Sullivan, Brian ^b   Ang, K Kian ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d LEICESTER ROYAL INFIRMARY   (United Kingdom)

^e FOX CHASE CANCER CENTER   (United States)

^f IntraBiotics Pharmaceuticals Inc   (United States)

^g AMERICAN COLLEGE OF RADIOLOGY   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ UNIVERSITY OF FREIBURG   (Germany)

^j INSTITUT GUSTAVE ROUSSY   (France)

^k BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^l VANDERBILT INGRAM CANCER CENTER   (United States)

^m BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

more..

Author keywords

Head and neck; Iseganan; Mucositis; Oral mucositis; Radiotherapy

Indexed keywords

DRUG THERAPY; HEALTH RISKS; PATIENT TREATMENT; RADIATION EFFECTS; RADIOTHERAPY; TUMORS;

ANTIMICROBIAL ACTIVITY; ORAL ULCERATION;

ONCOLOGY;

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ISEGANAN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH HYGIENE; MOUTH ULCER; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUESTIONNAIRE; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; STOMATITIS; SWALLOWING; SYMPTOMATOLOGY; THRUSH; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 10744229987     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)01627-4     Document Type: Article

References (14)

1. Trotti A. Toxicity in head and neck cancer A review of trends and issues . Int J Radiat Oncol Biol Phys. 47:2000;1-12.
2. Fu K., Pajak T., Trotti A., et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation to two variants of accelerated fractionation for head and neck squamous carcinoma First report of RTOG 90-03 . Int J Radiat Oncol Biol Phys. 48:2000;7-16.
3. Symonds P, Pulliam J, Redman R, et al. Endpoint evaluation of trials to reduce the severity of treatment induced oral mucositis [Abstract]. ASCO Proceedings 2002: 236a.
4. Rose-Ped A., Bellm L., Epstein J., et al. Complications of radiation therapy for head and neck cancer The patient's perspective . Cancer Nurs. 25:2002;461-467.
5. Sonis S.T. Mucositis as a biological process A new hypothesis for the development of chemotherapy-induced stomatotoxicity . Oral Oncol. 34:1998;39-43.
6. Symonds R.P., McIlroy P., Khorrami J., et al. The reduction of radiation oral mucositis by selective decontamination antibiotic pastilles A placebo-controlled double blind trial . Br J Cancer. 74:1996;312-317.
7. Okuno S.H., Foote R.L., Loprinzi C.L., et al. A randomized trial of a nonabsorbable antibiotic lozenge given to alleviate radiation-induced mucositis. Cancer. 79:1997;2193-2199.
8. Giles FJ, Miller CB, Hurd DD, et al. for the PROMPT-CT Trial Investigators. A phase III, randomized, double blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT Trial). Leuk Lymph. In Press.
9. Bellm L., Lehrer R.I., Ganz T. Protegrins New antibiotics of mammalian origin . Expert Opin Invest Drugs. 9:2000;1731-1742.
10. Chen J., Falla T.J., Liu H., et al. Development of protegrins for the treatment and prevention of oral mucositis Structure-activity relationships of synthetic protegrin analogues . Biopolymers. 55:2000;88-98.
11. Giles F.J., Redman R., Yazji S., et al. Iseganan HCl A novel antimicrobial agent . Expert Opin Invest Drugs. 11:2002;1161-1170.
12. Mosca D.a, Hurst M.A., So W., et al. IB-367, a protegrin peptide with in vitro and in vivo activities against the microflora associated with oral mucositis. Antimicrob Agents Chemother. 44:2000;1803-1808.
13. El-Sayed S., Nabid A., Shelley W., et al. Prophylaxis of radiation-associated mucositis in conventionally treated patients with head and neck cancer A double blind, phase III, randomized, controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucositis scoring system . J Clin Oncol. 20:2002;3956-3963.
14. Foote R., Loprinzi C., Frank A., et al. Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis. J Clin Oncol. 12:1994;2630-2633.